Alkermes Advisory Committee Hears More About Refuse-To-File Letter Thanks To Industry Rep
Executive Summary
US FDA’s decision to issue refuse-to-file action for Alkermes’ buprenorphine/samidorphan combo for major depressive disorder was one of the review issues brought to light by an unusually active advisory committee industry representative.